The company's financial performance showed a significant decline in revenue and an increase in net loss, which are negative indicators. The Co-Dx PCR testing platform, a key strategic initiative, is still pending regulatory approval, introducing uncertainty. The lack of discussion on shareholder returns and unclear management responses in the Q&A add to the negative sentiment. Given these factors, the overall outlook is negative, with potential for a -2% to -8% stock price movement.